Inside the research
Inspire Medical Systems, Inc.
INSP Research profile · latest available data
Price overview
$70.50
▲ +1.69 (+2.5%)
| 52w hi | $143.99 |
|---|---|
| 52w lo | $40.05 |
| Vol | 609.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.05
| Short | +0.04 |
|---|---|
| Medium | +0.13 |
| Long | -0.10 |
computed 2026-09-27
Key fundamentals
Inspire Medical Systems, Inc.
Healthcare · Medical Devices
| Market cap | $2.04B |
|---|---|
| Enterprise value | $1.75B |
| Trailing P/E | 15.56x |
| Forward P/E | 45.78x |
| EV / EBITDA | 24.49x |
| P / S (ttm) | 2.27x |
| Profit margin | 15.0% |
| Return on equity | 18.0% |
| Revenue growth | -7.6% |
| Debt / equity | 3.52 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.09 | |
| Sector | +0.08 | |
| Technical | +0.02 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Risk Metrics
| Beta vs SPX | 1.11 |
|---|---|
| Corr SPX | 0.28 |
| Annual vol | 64.6% |
| Annual ret | -34.0% |
| Sharpe | -0.53 |
| Max DD | -81.5% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-03 | Earnings Release, Reg FD Disclosure… | read |
| 2026-07-24 | Officer / Director Change | read |
| 2026-07-22 | Officer / Director Change, Exhibits | read |
| 2026-06-26 | Reg FD Disclosure, Exhibits | read |
| 2026-05-05 | Officer / Director Change, Bylaws Amendment… | read |
| 2026-05-04 | Earnings Release, Reg FD Disclosure… | read |
| 2026-02-11 | Earnings Release, Bylaws Amendment… | read |
| 2026-01-12 | Earnings Release, Officer / Director Change… | read |
| 2025-11-17 | Other Material Event | read |
| 2025-11-03 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-10 | Reg FD Disclosure, Exhibits | read |
| 2025-08-26 | Officer / Director Change, Reg FD Disclosure… | read |
SEC Filings
The Long Run
FY 2019–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $624.80M | +40.3% | |
| Gross profit | $778.76M | +104.7% | |
| Operating income | $50.95M | +41.2% | |
| Net income | $145.42M | — | |
| Cash from ops | $116.98M | +117.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $68.65 | $70.98 | $68.13 | $70.50 | 609.80K |
| Sep 24 | $69.11 | $70.58 | $68.65 | $68.81 | 580.60K |
| Sep 23 | $71.38 | $72.10 | $68.15 | $69.06 | 729.60K |
| Sep 22 | $75.32 | $76.10 | $71.19 | $71.30 | 1.12M |
| Sep 21 | $76.50 | $77.26 | $74.92 | $75.72 | 1.08M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →